ASX-Dividend-Report-Banner

AMS BioteQ Makes Debut at Medical Japan 2023: Bringing Innovative Healthcare into New Horizons

October 25, 2023 04:06 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 AMS BioteQ Makes Debut at Medical Japan 2023: Bringing Innovative Healthcare into New Horizons
Image source: Kalkine Media

TAIPEI, Oct. 25, 2023 /PRNewswire/ -- Medical Japan Tokyo was held grandly from October 11 to 13, gathering medical professionals, manufacturers, medical institutions, and research units from around the world. AMS BioteQ Co., Ltd. made its first appearance in the exhibition and became one of the spotlights. Founded in 2018, AMS BioteQ (TPE: 6864) specializes in the microbial field, particularly in solving the problem of antibiotic resistance. Utilizing its patented biotechnological process, ExtrO™, the company has successfully developed several technologies and products, including a novel natural antibacterial material called MediAce®, which could promote wound healing process.

Chairman of AMS BioteQ and the R&D team took a photo with Director Wei on the launch day of Medical Japan Tokyo 2023
Chairman of AMS BioteQ and the R&D team took a photo with Director Wei on the launch day of Medical Japan Tokyo 2023

Innovative Moist Treatment, Yielding Novel Wound Healing Process

AMS BioteQ has focused its R&D efforts on a new series of hydrophilic dressings called SIPSIP, made from environmentally friendly materials, which has excellent anti-adhesion, anti-scarring, and tissue regeneration capabilities. The SIPSIP series consists of three types of dressings: SIPSIP Foam, SIPSIP Pro, and SIPSIP Complex. The SIPSIP series offers three specialized wound care dressings: "Complex," "Pro," and "Foam." Each variant is designed with patented, non-allergenic, and highly absorbent features. "Complex" focuses on all-around care and scar prevention, "Pro" is ideal for sensitive skin and offers superior moisturizing, while "Foam" provides optimal absorbency and minimizes wound adhesion. These dressings are not only biocompatible and hydrophilic but have also been scientifically proven to promote wound healing and tissue regeneration in mouse models.

Captivating Global Interest across Multiple Sectors with Unique Technology

During the exhibition, AMS BioteQ initially estimated to receive 500 visitors, but the actual number exceeded 1,000, with an effective visitor ratio near 50%. In addition to local Japanese visitors, who made up 70% of the total, the remaining 30% came from mainland China, Hong Kong, Macau, Korea and Southeast Asian countries like Thailand, Singapore, Malaysia, the Philippines, and Indonesia. About 10% of the visitors were from Europe, the Middle East, and Africa, including countries like Belgium, Latvia, the Netherlands, Romania, Algeria, Saudi Arabia, and South Africa. The visitor demographic was diverse, including import-export traders, medical equipment agents, staff from hospitals and long-term care institutions, as well as many decision-makers.

Actively apply for regulatory permissions and gradually expand international research cooperation

In this exhibition, AMS BioteQ unveiled its innovative SIPSIP series of medical dressings, with plans to submit medical device license applications to both the FDA and TFDA by the end of 2023, targeting revenue growth for 2024. Accompanied by two experts from their R&D department, the company offered detailed insights into their promising new products, including the SIPSIP series and AMS-2140. This exhibition served as a pivotal platform for AMS BioteQ, as their cutting-edge products and technologies have not only opened a new direction in healthcare but also garnered significant attention from industry professionals and investors alike.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.